Subscribe
8 July 2025NewsBiotechnologyHa Kung Wong, Venable | Karen Martin, Ipsen | Nitin Virmalwar, Stoke Therapeutics | Jennifer Moitoso, Biogen

WATCH: Mastering the art of IP transactions—due diligence, valuation, and deal-making

LSPN brings together experts from Venable, Ipsen, Stoke Therapeutics, and Biogen to analyse best practices for IP transactions, from due diligence and valuation to structuring deals.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk




Editor's picks

Astellas win strengthens blockbuster drug's European position
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025

Editor's picks

Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025
Americas
Latham steps into dispute over $6bn treatment, replacing Kirkland
13 August 2025
Americas
BMS blocks biosimilar version of blockbuster cancer drug in India
21 July 2025
Europe
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
15 July 2025
Africa
Explainer: ARIPO’s role in Plant Variety Protection
15 July 2025
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

More features

‘This is not a rescue deal’: How an acquisition fits London firm's plan
Alston & Bird partner with strong Japanese ties jumps to new firm
Chinese invisible braces maker hits back at infringement claims
Renowned ITC litigator leaves Morgan Lewis to join competitor
‘Loopholes’ in ITC orders? Blindsided Masimo takes aim at US customs
Invisalign maker sues Chinese rival in Europe, US, and China
Astellas win strengthens blockbuster drug's European position
Roche sues over blockbuster cancer drug as key patent protection expires